Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to assess improvement in visual evoked potential, cognition, fatigue, micturation and walking impairment under 3 months of Fampyra treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients

NCT02146534

Multiple Sclerosis

COMPLETED PHASE4

Dalfampridine in Egyptian Patients With Multiple Sclerosis

NCT05730738

Multiple Sclerosis

UNKNOWN NA

Dimethyl Fumarate in Adrenomyeloneuropathy

NCT06513533

Adrenomyeloneuropathy Without Cerebral Involvement

RECRUITING PHASE2/PHASE3

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

NCT01645787

Spinal Muscular Atrophy

COMPLETED PHASE2/PHASE3

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN

NCT04973657

Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis EDSS 4-7

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fampyra group

Fampyra

Intervention Type DRUG

The will be given as per normal patient treatment plan

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fampyra

The will be given as per normal patient treatment plan

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients who according to the compound's Norwegian prescription guidelines are deemed eligible for the study, i.e. MS patients with impaired walking as determined by an EDSS 4-7. They do not need a past history of optic neuritis, cognitive failure, fatigue or difficulties micturating.

Exclusion Criteria

MS patients with contraindications to the compound according to the prescription guidelines.

Patients who have been exposed to Fampyra in the past Patients with an MS attack within last 3 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No